



# INVEST IN **VACCINES OF** THE FUTURE

#### **IMPORTANT INFORMATION – REFERENCE TO PROSPECTUS**

This marketing brochure has been prepared by Eurocine Vaccines AB ("Eurocine Vaccines" or the "Company"). Readers are requested to read The prospectus published by Eurocine Vaccines in connection with the Company's right issue (published on 3 June 2021) for a description of the risks associated with an investment in the Company. The prospectus is available for download on the Company's website ([www.eurocine-vaccines.com](http://www.eurocine-vaccines.com)).

#### **Exercise of warrants of series TO 4**

**Exercise period: 14–28 March 2022**

# **The current pandemic** has reminded us of the importance of our efforts to research and develop innovative ways to both protect and treat patients

**Internationally and in Sweden,** vaccines and vaccine developers are now increasingly emphasised as important societal functions in ensuring global public health - new vaccines are needed to keep pace with constantly mutating viruses and safeguard the health of future generations.

Sweden is committed to the field, with the ambition of being a leading life science nation that promotes start-ups, investments and research collaborations.

Recently, the government commissioned Vinnova to set up an innovation hub to enable the production of advanced medicines and vaccines - initiatives that will strengthen innovation and create better conditions for the life science industry and vaccine development companies like Eurocine Vaccines.

As society returns to normal, the need for safe and effective vaccines has had a permanent impact on the life science industry. Ground-breaking technologies, rapid drug development and greater levels of collaboration between the pharmaceutical industry and governments are the new reality, which will require agile organisations.



**“The importance of vaccines to our society has never been greater. Developing effective vaccines, tests and treatments is the only way to prevent and protect against infectious diseases. That is why we need to intensify our efforts.”**

**Emanuele Montomoli, Professor, University of Siena, Italy**

- internationally renowned vaccine expert and board member of ISIRV, Vismederi and Eurocine Vaccines



## The Company

– Eurocine Vaccines’ portfolio strategy

Eurocine Vaccines is developing a solid portfolio of vaccine candidates at different stages, with significant patient benefits. The Company bridges the gap between innovation and market, and its expertise extends through all stages of vaccine development, from discovery to commercialization.

The ambition is to develop the Company’s portfolio of vaccine candidates to proof-of-concept in humans and continuously seek opportunities to refine and broaden each of them. This portfolio strategy allows more innovations to reach the market faster.

Discover how we bridge the gap between innovation and the market.



### Identify, evaluate and select

We are constantly exposed to promising medical innovations which are evaluated from a variety of aspects. This requires a thorough approach based on combined knowledge of vaccinology, pharmaceuticals, law, business development and marketing – a time-consuming process in the laboratory as well as at the desk where the most promising vaccine candidates are selected.

# 1

# 2

### Develop and improve

When a promising candidate is added to our portfolio, an intense development journey begins, where our focus is to maximize each candidate’s value. This can be done through optimised study design, simplified administration, application broadening, or even spin-offs into new products.

**Annual Review 2021**

Read more about the progress we’ve made over the past year and hear CEO Hans Arwidsson reflect on the future



## The lead candidate against chlamydia

Eurocine Vaccines' lead candidate targets the indication chlamydia, for which there is currently a lack of preventive vaccines. The WHO estimates that over 130 million new cases occur each year and an implementation of vaccination in adolescents has been proposed, similar to the existing vaccination programmes against HPV.

Chlamydia vaccines are estimated to have a global sales potential comparable to HPV vaccines, where Gardasil and Cervarix dominate.

Together, these two vaccines sold for more than \$4.2 billion in 2020 and are projected to reach \$6.9 billion in 2026, according to Globe Life Sciences Ltd. A successful chlamydia vaccine is also expected to contribute to a reduction in antibiotic use - chlamydia infection is currently treated primarily with antibiotics - which would reduce the pressure for antibiotic resistance, a serious threat to global public health.



**Thomas Eldered, CEO Flerie Invest**

– principal shareholder of the Company, guarantor of the current issue and former co-founder of Recipharm

**“We see great potential in the value that Eurocine Vaccines creates, with its chlamydia vaccine candidate and vaccine portfolio under development, which is well in line with Flerie Invest’s investment strategy. Together, we contribute to advancing the development of medical innovations that meet important patient needs.”**

## Planned activities with the chlamydia candidate

### 2022

- Continued development of industrially scalable manufacturing process.
- Production of study products for the upcoming study.
- Toxicological study initiated.
- Continued preclinical immunological studies.

### 2023

- Toxicological study reported.
- Submission of clinical trial application.
- Manufacturing of study products for the clinical study according to GMP.
- Initiation of the first clinical study.

### 2024

- Clinical study is evaluated and reported.
- Intensified business development and preparation for out-licensing.
- Design, plan and prepare Phase IIA clinical trial to start around year end 2024.

[Read more](#)

Read more about chlamydia, treatment, and the market. Also, meet the inventors in a video where they talk about the background to the revolutionary technology.



## CEO Hans Arwidsson

The importance of vaccines to our society has never been more evident – during the pandemic, the world has seen that vaccination is a highly effective method of preventing and protecting against infectious diseases.

The development of safe and effective vaccination against diseases that cause significant infection and mortality has been one of the major scientific advances of the 21st century. It is estimated that vaccination prevents millions of deaths annually – medical research-driven innovations that improve public health globally.

Eurocine Vaccines selects vaccine antigens that meet major patient needs. Our portfolio strategy includes innovative candidates at various stages that are advanced based on the Company's significant knowledge and experience in the field.

The proceeds from this warrant exercise will allow us to make further progress with the vaccine portfolio and advance the vaccine candidate against chlamydia. Near-term objectives

include scale-up and manufacturing of study product and completion of toxicology study ahead of planned start of clinical trial in H1 2023.

I invite you all to participate and exercise your warrants of series TO 4, an important investment in the future development of Eurocine Vaccines.

### Hans Arwidsson

CEO, Eurocine Vaccines AB

## Summary of the offer

### Exercise period:

14 – 28 March 2022.

### Subscription price:

Each warrant of series TO 4 entitles the holder to subscribe for one (1) new share in Eurocine Vaccines at a price of SEK 1.41.

### Last day for trading with warrants:

24 March 2022.

### Number of shares outstanding in Eurocine Vaccines before exercise of warrants:

14,211,741 shares.

### Valuation in current offering:

Approximately 20 MSEK.

### Issue volume:

If the warrants of series TO 4 are fully exercised, the Company will receive approximately SEK 4.5 million before issue costs.

### Top-down guarantee and subscription commitment:

Eurocine Vaccines has received a subscription commitment and a guarantee commitment for a total of approximately 61.4 percent of the issue volume of TO 4 (corresponding to a maximum of 1,939,443 shares in the Company). The subscription commitment corresponds to approximately 11.4 percent (360,361 shares) and the guarantee commitment corresponds to approximately 50 percent (1,579,082 shares). as a top-down guarantee, which means that if TO 4 are used to about 50 percent, guarantee subscription will be conducted up to fully subscribed TO 4.

## Terms for warrants of series TO 4 in brief

There are 3,158,164 outstanding warrants of series TO 4. The holder of warrants of series TO 4 has the right to subscribe for one (1) new share in Eurocine Vaccines for each warrant held at a price of SEK 1.41 per share. Subscription of new shares in Eurocine Vaccines, by exercise of warrants of series TO 4, can be made during March 14 – March 28, 2022. Subscription of new shares is made by cash payment no later than 5:00 p.m. CEST on March 28, 2022.

### Action from you as a warrant holder is required – How to exercise your warrants of series TO 4

In order for your warrants not to expire worthless your action is required. You must apply for subscription of new shares, by exercise of warrants, no later than 5:00 p.m. CEST March 28, 2022, alternatively sell your warrants no later than March 24, 2022.

### You can have your warrants registered in two ways:

1. In a securities custody account with a bank or other nominee (for example, Avanza or Nordnet), in an investment savings account (Sw. Investeringssparkonto) or endowment account (Sw. Kapitalförsäkring). Your warrants are then nominee registered.
2. In a VP-account (a VP-account starts with three zeros). Your warrants are then directly registered.

### If your warrants are nominee registered

Subscription and payment of new shares, by exercise of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with instructions from each such bank or nominee. Usually, the bank/nominee sends out a digital notice to the account holder, otherwise it is enough to log into the securities custody account from the first day in the exercise period in order to get instructions on how to exercise warrants for subscription of new shares. If you do not find these instructions, please contact your bank or trustee. Please note that banks and other nominees may set different time limits for the last day for subscription, hence it is recommended to contact the account-holding bank/nominee early in the exercise period. This folder will be sent out to most nominee registered warrant holders. Subscribed and paid for shares may be entered as “interim shares” or “IA” into your securities custody account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in Eurocine Vaccines.

### If your warrants are directly registered

No VP-account statement will be sent out. Subscription of new shares, by exercise of warrants, shall be made by sending a completed subscription form to Nordic Issuing. In conjunction with sending the completed subscription form, payment must be made to Nordic Issuing in accordance to the payment details stated on the subscription form. Subscription form along with this folder will be sent to VP-account holders. The subscription form and folder are also available at the respective websites of Eurocine Vaccines ([www.eurocine-vaccines.com](http://www.eurocine-vaccines.com)), Sedermera Corporate Finance ([www.sedermera.se](http://www.sedermera.se)), and Nordic Issuing ([www.nordic-issuing.se](http://www.nordic-issuing.se)).

Completed subscription form and payment must be registered with Nordic Issuing no later than 5:00 p.m. CEST March 28, 2022. Subscribed and paid for shares will be entered as “interim shares” or “IA” into your VP-account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in Eurocine Vaccines.

### Subscription over EUR 15,000 where applicable

In the event that your subscription amounts to or exceeds EUR 15,000, money laundering forms must be completed and submitted to Nordic Issuing at the same time as payment is made according to the Swedish law (2017:630) on measures against money laundering and terrorist financing. Please note that interim shares cannot be delivered out even though payment has been received until the money laundering form has been approved by Nordic Issuing. Money laundering forms are available from Nordic Issuing.

### Important dates for warrants of series TO 4

<b>March 14, 2022</b>	Exercise period begins
<b>March 24, 2022</b>	Last day of trading in the warrant
<b>March 28, 2022</b>	Exercise period ends
<b>March 31, 2022</b>	Planned date for publication of the warrant exercise outcome
<b>April 25, 2022</b>	Planned date for conversion of interim shares to ordinary shares

**NOTE** – In order for your warrants not to expire worthless, you must actively subscribe and pay for shares no later than 5:00 p.m. CEST March 28, 2022, alternatively sell your warrants no later than March 24, 2022.

In case of any questions regarding warrants in Eurocine Vaccines, please contact Nordic Issuing. Sedermera Corporate Finance and Nordic Issuing acts, respectively, as financial advisor and issuing agent for Eurocine Vaccines in connection with the issue. Markets & Corporate Law Nordic AB acts as legal advisor.

Nordic Issuing  
Phone: +46 (0)40-632 00 20  
E-mail: [info@nordic-issuing.se](mailto:info@nordic-issuing.se)

[Link to subscription form](#)

